Eli Lilly is a global pharmaceutical company dedicated to discovering, developing, manufacturing, and marketing innovative medicines that address some of the world's most challenging health issues. The company focuses on areas such as diabetes, oncology, immunology, and neurodegenerative diseases, providing a wide range of treatments designed to improve patient outcomes and quality of life. Eli Lilly is committed to scientific advancement and works collaboratively with healthcare professionals and researchers to bring new therapies and solutions to market, ensuring access to life-saving medications for patients around the globe. Read More
DALLAS, TX - October 01, 2026 - Cancer immunotherapy, advanced DNA sequencing, Alzheimer’s research and predictive human tissue testing are putting seven healthcare companies on the 2026 watchlist. ImmunityBio, Pacific Biosciences, IGC Pharma, VivoSim Labs, PDS Biotechnology, Connect Biopharma and AEON Biopharma offer distinct developments for investors to follow as the year enters its final quarter.
JNJ trades at a 28% discount on valuation while LLY's cardiometabolic drugs drive 82% of revenue, each bet carries distinct growth and concentration risks.
Delcath Systems, Viking Therapeutics and AxoGen show growth potential backed by analyst Moderate Buy ratings and strong institutional ownership, despite risks like dilution and patent cliffs.
AutoZone, Eli Lilly, Meta Platforms, and Costco all trade at high share prices, making them candidates for stock splits as analysts raise price targets and cite strong fundamentals.
Bristol Myers Squibb trades at a fraction of Eli Lilly's valuation while generating substantial free cash flow, but concentration risk and explosive growth tell very different stories.
Dallas TX - Sept. 28, 2026 - From AI data centers and Alzheimer’s research to drug safety testing and humanoid robots, six small-cap companies are approaching developments that could shape their next phase of growth.
Dallas TX - Sept. 28, 2026 - VivoSim Labs Inc. (NASDAQ: VIVS) is developing human-relevant testing technologies designed to identify unsuccessful drug candidates earlier, potentially improving the economics of pharmaceutical development.
